An Investigational Study of SHR6390 in Participants With Mild to Moderate Liver Impairment and Healthy Participants
NCT04631575 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24
Last updated 2020-11-17
Summary
The purpose of this study is to investigate SHR6390 in participants with different levels of liver function
Conditions
- Hepatic Impairment
- Healthy Participants
Interventions
- DRUG
-
SHR6390
SHR6390, PO,single-dose
Sponsors & Collaborators
-
Jiangsu HengRui Medicine Co., Ltd.
lead INDUSTRY
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- BASIC_SCIENCE
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2020-12-31
- Primary Completion
- 2021-03-31
- Completion
- 2021-03-31
More Related Trials
-
Relative Bioavailability Study of SHR3680
NCT04903158 ·Status: UNKNOWN ·Phase: PHASE1
-
Investigation of Pharmacokinetics and Safety of HRS-7535 in Subjects With Hepatic Impairment and Normal Hepatic Function
NCT06961643 ·Status: COMPLETED ·Phase: PHASE1
-
A Trial of SHR6390 in Healthy Caucasian Volunteers
NCT04301804 ·Status: COMPLETED ·Phase: PHASE1
-
A Trial of HR17031 Injection With Hepatic Insufficiency
NCT05151705 ·Status: UNKNOWN ·Phase: PHASE1
-
A Study to Compare Pharmacokinetic and Safety Profiles of Different Formulations of SHR-1314 After Subcutaneous Injection in Healthy Subjects
NCT04326881 ·Status: UNKNOWN ·Phase: PHASE1
-
Study to Evaluate the Mass Babance and Biotransformation of [14C]SHR6390 in Healthy Adult Male Volunteers
NCT04616742 ·Status: COMPLETED ·Phase: PHASE1
-
Investigation of Pharmacokinetics,Safety,and Pharmacodynamics of HRS-5965 in Subjects With Hepatic Impairment
NCT06674915 ·Status: COMPLETED ·Phase: PHASE1
-
A Bioavailability Study of SHR1459 on Healthy Chinese Volunteers
NCT04395053 ·Status: COMPLETED ·Phase: PHASE1
-
Pharmacokinetics, Dialysability and Safety of HRS-9231 in Healthy Volunteers and in Patients With Impaired Renal Function
NCT06657560 ·Status: COMPLETED ·Phase: PHASE1
-
Study to Evaluate Orelabrutinib Tablets in Subjects With Hepatic Impairment and Healthy Subject
NCT05684653 ·Status: UNKNOWN ·Phase: PHASE1
-
Study of Bioavailability, Pharmacodynamics and Safety of SHR-1209 Administered by Single Subcutaneous Injection at Different Sites in Healthy Volunteers
NCT05370950 ·Status: COMPLETED ·Phase: PHASE1
-
Study to Assess Pharmacokinetics, Safety, and Tolerability of MT-7117 in Subjects With Normal and Impaired Hepatic Function
NCT04116476 ·Status: COMPLETED ·Phase: PHASE1
-
GP681 in Volunteers With Hepatic Impairment Compared With Healthy Volunteers
NCT05814926 ·Status: COMPLETED ·Phase: PHASE1
-
Phase 1 Study in Healthy Participants and Participants With Kidney Dysfunction
NCT06383897 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
Pharmacokinetics Study of MCI-186 in Subjects With Mild or Moderate Hepatic Impairment
NCT03289234 ·Status: COMPLETED ·Phase: PHASE1
-
Study to Evaluate the Mass Balance and Biotransformation of [14C]SHR1459 in Healthy Adult Male Volunteers
NCT05095337 ·Status: UNKNOWN ·Phase: PHASE1
-
Pharmacokinetics, Safety and Tolerability of ITF2357 in Participants With Chronic Hepatic Impairment and With Normal Hepatic Function
NCT06736223 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of HDM1002 in Subjects With And Without Varying Degrees Of Hepatic Impairement
NCT06985615 ·Status: RECRUITING ·Phase: PHASE1
-
Single-dose Study to Investigate the Plasma PK of KW-6356 and Its Major Metabolite
NCT04190654 ·Status: COMPLETED ·Phase: PHASE1
-
A STUDY TO COMPARE THE PHARMACOKINETICS OF PF-06835919 IN PARTICIPANTS WITH AND WITHOUT HEPATIC IMPAIRMENT
NCT04193436 ·Status: COMPLETED ·Phase: PHASE1
-
Pharmacokinetics of HR17031 Injection in Healthy Subjects
NCT05031871 ·Status: COMPLETED ·Phase: PHASE1
-
Effect Of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of PF-06865571 In Subjects With Hepatic Impairment and in Healthy Subjects
NCT04091061 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Investigate Pharmacokinetics (PK) and Safety of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function
NCT06858696 ·Status: RECRUITING ·Phase: PHASE1
-
Safety and Pharmacokinetics/Pharmacodynamics of HSK3486 in Patients With Hepatic Impairment
NCT04145596 ·Status: COMPLETED ·Phase: PHASE1
-
STUDY OF PF-06882961 IN PARTICIPANTS WITH AND WITHOUT VARYING DEGREES OF HEPATIC IMPAIREMENT
NCT04604496 ·Status: COMPLETED ·Phase: PHASE1